A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

• Status: NOT_YET_RECRUITING
• Trial end date: 2030-11-01

Summary

This three-arm randomized phase 2 trial will enroll advanced clear cell RCC patients (all IMDC risk groups). Patients will be randomized 2:2:1 to either Arm A (fianlimab/ cemiplimab/ ipilimumab), Arm B (fianlimab/ cemiplimab), or Arm C (standard ipilimumab/ nivolumab), respectively.

• Phase: PHASE2

Details

• Lead Sponsor: Brian Rini
• Collaborators: Regeneron Pharmaceuticals; Vanderbilt-Ingram Cancer Center
• Treatments: cemiplimab; Ipilimumab; Nivolumab